Quick navigation menu :

  1. Go to the content
  2. Go to main section's menu
  3. Go to Search tool
  4. Go to Help menu
  5. Go to modules
  6. Go to the list of keyboard shortcuts

This site uses cookies to store information on your computer. Some cookies on this site are essential and the site won’t work as expected without them. To learn more about cookies and their benefits, please view our cookies policy. You could also decide what kind of cookie the website could use or not use on our cookies settings page.
By closing this message or navigating within the website, you consent to our use of cookies on this device in accordance with our cookie policy unless you have disabled them.

Help menu :

  1. Sanofi Worldwide |
  2. Our UK Websites |
  3. Global Business Websites |
  4. Contact us |
  5. Site map |
  6. Help
  1. RSS
  2. Font size

    Reduce font size Increase font size  

Press Room

Contact us


One Onslow Street

Press enquiries only:

0845 372 6263


01483 505 515


01483 554 801


Content :

Fear and shame leading to people with Type 2 diabetes risking future life threatening conditions

New campaign launches to highlight how emotional and psychological factors are impacting effective diabetes management


Guildford, United Kingdom – 14 November 2016 – Sanofi today announced that new research reveals that negative emotions are jeopardising people living with Type 2 (T2) diabetes’* ability to effectively manage their condition. A quarter of people with T2 diabetes feel anxious or fearful about getting ‘hypos’ (low blood glucose levels), with 42% preferring to have high blood glucose levels instead of risking another ‘hypo’, despite this risking life threatening conditions in the future.1

*Please note that all references in the press release to ‘people with type 2 diabetes’ refer only to those who are diagnosed and on insulin

The UK has the worst T2 diabetes blood glucose levels in Europe2, so Sanofi is launching a new campaign dedicated to helping patients - ‘Highs & Lows: Better Balance for a Better Future’, that includes a Sanofi sponsored patient support website, https://www.diabeteshighsandlows.co.uk/ to help the 52% of patients with T2 diabetes who find it challenging to balance their blood glucose levels or who worry about doing so.1 Another Sanofi-funded study conducted in UK adults with Type

1 and Type 2 diabetes and published in the journal Diabetic Medicine, showed even modest and sustained improvement in blood glucose control could help prevent almost a million serious medical complications such as eye disease, kidney disease, foot ulcer and amputations, and potentially blindness, which could avoid billions in future NHS costs.3

Dr Max Pemberton, GP and Psychiatrist at St Anne’s Hospital, London explains: “This research shows that people with T2 diabetes are making fear-driven decisions in the ‘here and now’ to prevent low blood glucose levels, without considering that high blood glucose levels can have serious implications on their health in the future as well. They need more support in order to be successful at this blood sugar ‘balancing act.”

** DiabetesHighsAndLows.co.uk is a patient support website, developed and funded by Sanofi.

The Sanofi research also revealed that negative emotions are stopping people managing their condition. People living with T2 diabetes believe that others think they are to blame (15%), some believing that people think they are just greedy (14%).1 This is in combination with 25% only telling close friends, family or their healthcare professional about their condition, and 58% feeling self- conscious or avoiding injecting in front of other people.1

Dr Pemberton, adds: “It’s clear that those with T2 diabetes feel judged by a ‘crowd’ of people who they think blame them for having the condition in the first place. It’s worrying that people feel that they have to hide their condition from others for fear of being criticised. This can lead to them not injecting on time because they wait until no one is around, or making bad food decisions during social occasions or not sticking to their meal time routine, which can have an impact on their blood sugar levels.”

Dr Mike Baxter, medical therapy expert at Sanofi UK commented: “Our research shows that there is a need in the UK for better support for people with type 2 diabetes – not just in terms of the medical management of the disease, but also the emotional and psychological aspects of the condition. Almost a quarter of patients blame themselves (22%), or feel they’ve let themselves down (24%), if they can’t or don’t manage their blood sugars effectively. Instead of this feeling of blame and failure, we want to help them feel motivated to seek the help that they may need to navigate the complex blood sugar ‘balancing act’. At this time, although the importance of psychological support in helping people to manage their condition is well recognised and the benefits of improved blood glucose control on reducing diabetic complications is well documented, there is a clear lack of adequate psychological support for people with diabetes. Consequently, the level of diabetic control in a large number of people with diabetes in the UK remains unacceptably high, exposing them to high risks of developing preventable diabetic complications”

The Sanofi ‘Diabetes Highs and Lows: Better Balance for a Better Future’ campaign aims to help people feel in control and positive about how they can balance their blood sugar levels. The new campaign website, https://www.diabeteshighsandlows.co.uk/, includes key information on recognising and managing blood glucose highs and lows for both patients and carers.

About the Sanofi Market Research

Funded by Sanofi, the market research was carried out in September-October 2016 amongst a nationally representative UK-wide sample of people diagnosed with type 2 diabetes who are taking insulin.

About Sanofi

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Merial. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward- looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidat es as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2015. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.


Media Relations

Alexandre Morvan

Tel. : +44 (0) 7710 388101 alexandre.morvan@sanofi.com


1 Sanofi Data on File 2016. “Highs and lows: better balance for a better future” market research

2 Khunti K et al. Study of Once Daily Levemir (SOLVETM) insights into the timing of insulin initiation in people with poorly controlled Type 2 diabetes in routine clinical practice. Diabetes, Obesity and Metabolism (2012)

3 Baxter et al, Estimating the impact of better management of glycaemic control in adults with Type 1 and Type 2 diabetes on the number of clinical complications and the associated financial benefit. Diabetic Medicine (2016). DOI: 10.1111/dme.13062

Date of preparation: November 2016 - Job bag number: SAGB.DIA.16.11.1041

Updated: November 14, 2016

Module :

Corporate Information

Corporate Information